Screener / SEC EDGAR /CIK 0000313143 /10-K filed May 20, 2026, compared with May 21, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Haemonetics Corp HAE

Compare with peers Embed
SEC comment letters, last 20 years

1 review of HAE's filings by SEC staff

UPLOAD and CORRESP
Reviews 1 latest letter Jan 12, 2017
Questions asked 1 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 1 UPLOAD
  2. 2. Questions in them 1 numbered comments
  3. 3. Company replies 1 CORRESP
  4. 4. Reviews closed 1 of 1 closing letter

Half the closed reviews took 21 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended April 2, 2016

2017-01-12 to 2017-02-02 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2017-02-02
Non-GAAP measuresSegments
Financial Statements · Note 14. Segment and Enterprise-Wide Information, page 85
SEC asked
We note that on page 86 you provide certain non-GAAP operating income measures. Please revise future filings to remove non-GAAP measures from the footnotes to your financial statements. Refer Item 10(e)(1)(ii)(C) of Regulation S-K. In future filings provide a reconciliation of segment operation income that is consistent with the guidance in ASC 280-10-50-30 and 280-10-55-49.
HAE answered
We undertake in future filings to remove references to total segment income on a non-GAAP basis from the footnotes to our financial statements and provide a reconciliation of segment operation income consistent with the guidance in ASC 280-10-50-30 and 280-10-55-49.

We trust that the foregoing is responsive to your comments.

400 Wood Road

Braintree, MA 02184-9114

Tel: 781.848.7100 www.haemonetics.com

In accordance with your request, we acknowledge that:

• The Company is responsible for the adequacy and accuracy of the disclosure in the filing; and

• Staff comments or changes to
Rest of the answer

disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing

Read in the reply
In its next report

First report after the company's reply of Jan 26, 2017: 10-Q filed Feb 6, 2017 ↗, against the 10-Q filed Nov 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2017-02-02

Letters without questions

Other letters

UPLOAD and CORRESP
1 other letter: notices that a filing will not be reviewed, requests to declare a registration effective, and the like
  • Apr 4, 2013 · SEC: review completed · Haemonetics Corporation · Form 10-K for the Fiscal Year Ended March 31, 2012 · Filed...

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 4 letters filed since 2013-04-04. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HAE/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.